Blydt-Hansen, I. et al. 2025. Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program. Journal of Hematology. 14, 5 (Oct. 2025), 257–261. DOI:https://doi.org/10.14740/jh2113.